Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cadrenal Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CVKD
Nasdaq
8731
https://www.cadrenal.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cadrenal Therapeutics Inc
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
- Apr 20th, 2024 1:56 pm
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
- Apr 11th, 2024 8:30 pm
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
- Apr 9th, 2024 1:00 pm
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
- Mar 11th, 2024 1:00 pm
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
- Feb 26th, 2024 2:00 pm
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
- Feb 8th, 2024 2:00 pm
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
- Jan 31st, 2024 2:00 pm
Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation
- Jan 30th, 2024 10:22 am
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
- Jan 24th, 2024 2:00 pm
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
- Jan 4th, 2024 2:00 pm
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
- Dec 19th, 2023 2:00 pm
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
- Dec 12th, 2023 2:00 pm
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
- Nov 30th, 2023 9:15 pm
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
- Nov 9th, 2023 2:00 pm
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
- Oct 9th, 2023 8:15 pm
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
- Sep 5th, 2023 12:00 pm
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
- Aug 30th, 2023 12:00 pm
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 28th, 2023 8:15 pm
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
- Aug 10th, 2023 1:00 pm
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
- Aug 1st, 2023 1:00 pm
Scroll